{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"34","value":"17"}]}],"title":"Neutrophils"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"147","value":"11"}]}],"title":"Platelets"}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"Median number of days after transplantation to a neutrophil count less than 500 neutrophils per microliter and a platelet count less than 50,000 platelets per microliter.","dispersionType":"Full Range","groups":[{"description":"See Detailed Description\n\nrituximab: Given IV\n\ncyclosporine: Given orally\n\nfludarabine phosphate: Given IV\n\nmycophenolate mofetil: Given orally\n\nyttrium Y 90 ibritumomab tiuxetan: Given IV\n\nperipheral blood stem cell transplantation: Undergo transplantation\n\nallogeneic hematopoietic stem cell transplantation: Undergo transplantation\n\ntotal-body irradiation: Undergo TBI","id":"OG000","title":"Treatment (90Y Ibritumomab Tiuxetan, Hematopoietic Transplant)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"At day +100","title":"Engraftment and Hematopoietic Toxicity","type":"SECONDARY","unitOfMeasure":"days"}